GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumito AB (NGM:LUMITO) » Definitions » Debt-to-Equity

Lumito AB (NGM:LUMITO) Debt-to-Equity : 0.19 (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Lumito AB Debt-to-Equity?

Lumito AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr20.00 Mil. Lumito AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Lumito AB's Total Stockholders Equity for the quarter that ended in Jun. 2024 was kr107.45 Mil. Lumito AB's debt to equity for the quarter that ended in Jun. 2024 was 0.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lumito AB's Debt-to-Equity or its related term are showing as below:

NGM:LUMITO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1   Med: 0.15   Max: 0.19
Current: 0.19

During the past 7 years, the highest Debt-to-Equity Ratio of Lumito AB was 0.19. The lowest was 0.10. And the median was 0.15.

NGM:LUMITO's Debt-to-Equity is ranked better than
57.07% of 191 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.23 vs NGM:LUMITO: 0.19

Lumito AB Debt-to-Equity Historical Data

The historical data trend for Lumito AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumito AB Debt-to-Equity Chart

Lumito AB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial - - - - -

Lumito AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.10 0.19

Competitive Comparison of Lumito AB's Debt-to-Equity

For the Diagnostics & Research subindustry, Lumito AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumito AB's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lumito AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lumito AB's Debt-to-Equity falls into.



Lumito AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lumito AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Lumito AB's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lumito AB  (NGM:LUMITO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Lumito AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Lumito AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumito AB Business Description

Traded in Other Exchanges
N/A
Address
Magistratsvagen 10, Lund, SWE, SE-226 43
Lumito AB is a Swedish company that specializes in the medical research and development of imaging technology for use in digital pathology. It has developed a development and business plan for the development of an instrument for digital pathology that improves the quality of tissue sample mapping.

Lumito AB Headlines

No Headlines